Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Change in Account Payables (2016 - 2025)

Catalyst Pharmaceuticals' Change in Account Payables history spans 16 years, with the latest figure at $2.1 million for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 58.13% year-over-year to $2.1 million; the TTM value through Dec 2025 reached -$5.4 million, down 399.83%, while the annual FY2025 figure was -$5.4 million, 399.83% down from the prior year.
  • Change in Account Payables reached $2.1 million in Q4 2025 per CPRX's latest filing, down from $3.6 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $10.2 million in Q4 2023 to a low of -$5.7 million in Q2 2025.
  • Average Change in Account Payables over 5 years is $347300.0, with a median of $195500.0 recorded in 2022.
  • The largest YoY upside for Change in Account Payables was 8937.5% in 2022 against a maximum downside of 873.7% in 2022.
  • A 5-year view of Change in Account Payables shows it stood at $16000.0 in 2021, then soared by 8937.5% to $1.4 million in 2022, then soared by 605.19% to $10.2 million in 2023, then tumbled by 50.67% to $5.0 million in 2024, then crashed by 58.13% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Change in Account Payables are $2.1 million (Q4 2025), $3.6 million (Q3 2025), and -$5.7 million (Q2 2025).